Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Gilead Files Once-Daily Integrase Inhibitor Elvitegravir With FDA

Jul 01 2012

• By Emily Hayes

Related Content

Profile Of Viiv’s Unboosted Dolutegravir Emerges With First Phase III Results

Apr 03 2012

With Isentress Sales Booming, New Integrase Inhibitors Step Up To The Plate

Mar 01 2010

Related Companies

Gilead Sciences, Inc.

Japan Tobacco Inc.

Merck & Co., Inc.

ViiV Healthcare

GSK plc

Pfizer Inc.

Abbott

Shionogi & Co. Ltd.

Additional Topics

Regulation BioPharmaceutical

More from Archive

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window